Compare FMNB & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMNB | FBRX |
|---|---|---|
| Founded | 1887 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 852.7M | 899.4M |
| IPO Year | 2010 | 2017 |
| Metric | FMNB | FBRX |
|---|---|---|
| Price | $14.43 | $44.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $15.00 | ★ $67.00 |
| AVG Volume (30 Days) | 532.5K | ★ 824.3K |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.89% | N/A |
| EPS Growth | 18.85 | ★ 61.30 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $279,922,000.00 | $36,000.00 |
| Revenue This Year | $52.63 | N/A |
| Revenue Next Year | $8.28 | N/A |
| P/E Ratio | $39.58 | ★ N/A |
| Revenue Growth | ★ 3.89 | N/A |
| 52 Week Low | $12.23 | $9.23 |
| 52 Week High | $15.50 | $45.36 |
| Indicator | FMNB | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 83.89 |
| Support Level | $13.75 | $24.72 |
| Resistance Level | $14.68 | N/A |
| Average True Range (ATR) | 0.26 | 3.87 |
| MACD | -0.03 | 2.90 |
| Stochastic Oscillator | 43.24 | 92.19 |
Farmers National Banc Corp is a financial holding company based in the U.S. Along with its subsidiaries, it operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The group offers a full range of commercial and retail banking services, including checking accounts, savings accounts, time deposit accounts, commercial, mortgage, and installment loans, safe deposit boxes, ATMs, internet banking, and other banking services. Additionally, it offers personal and corporate trust services in the areas of estate settlement, trust administration, employee benefit plans, and retirement services; insurance products, and other financial products and services. The group's reportable segments are Bank, which generates the maximum revenue, and Trust.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.